EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 313 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Studying “Total Diet” and Its Impact on Health, Including Cancer Risk October 25, 2018 Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours March 1, 2021 FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma April 14, 2021 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin June 12, 2025 Load more HOT NEWS A cut above: Making drug discovery more efficient using CRISPR FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... Acing it: The ambitious early career researchers driving progress in cancer... FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated...
